Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15764 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Matthew R Weir. Beteiligte Einrichtung: Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Practice Guidelines as Topic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
In the US, approximately 11% of the population have diagnosed diabetes and nearly 40% have prediabetes. In addition, chronic kidney disease (CKD) affects 14% of the US population including up to 40% of those with diabetes. Cardiovascular disease (CVD) remains the leading cause of death worldwide where it affects approximately half of adults. The presence of CKD or diabetes doubles the risk of cardiovascular events. When both CKD and diabetes occur in the same patient the risks are further increased. The clinical problems of hypertension, hyperglycemia, and hyperlipidemia are all closely related with obesity, metabolic syndrome, Type 2 diabetes, CKD, atherosclerotic cardiovascular disease, heart failure and non‐alcoholic fatty liver disease and metabolic dysfunction‐associated steatohepatitis. The increasing frequency of obesity has driven increases in all of these medical comorbidities. These conditions frequently cluster together in the same patient exacerbating the risk of morbidity and mortality. They are also associated with cognitive dysfunction/dementia, pulmonary diseases, cancers, gastrointestinal diseases, immune system abnormalities, and inflammatory disorders. Only 6.8% of adults in US meet all targets for cardiovascular risk management with significant disparities based on race and ethnicity. Given the complexity of these multisystem problems in people with diabetes and obesity, it would seem reasonable to attempt to diagnose and treat many of the comorbidities earlier in the course of disease rather than wait for substantial end organ dysfunction to occur. The American Diabetes Association (ADA) has recently published a consensus statement recommending early screening for the diagnosis of heart failure, CKD and diabetes, recognizing both the frequency and gravity of this combination. Likewise, there are recommendations in the guidelines to facilitate screening for microalbuminuria, blood pressure, glycemic control and lipids earlier in patients at risk rather than wait and treat as a secondary prevention program. Thus, the general principle is to facilitate earlier recognition and diagnosis and provide treatment before downstream target organ complications occur. This review will focus on CVD and risk management based on newest recommendations and standards of care in people with diabetes by the ADA. The main considerations in the treatment of people with diabetes are glycemic control, blood pressure, lipids, and the use of medications with proven cardiorenal disease progression capability to prevent or delay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Matthew R Weir
Zitieren
APA
Weir, M. R. (2024). Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15764
Vancouver
Weir MR. Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15764
BibTeX
@article{Weir2024,
author = {Weir, Matthew R},
title = {Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15764}
}
EUVIMED